3BP-227 / FPI-2059 / IPN01087is targeting the neurotensin receptor 1 (NTR1) which is highly expressed on the cancer cells of ductal pancreatic adenocarcinoma and several other tumor entities. The program is partnered with Fusion Pharmaceuticals globally. Using a theranostic approach,225Ac-FPI-2059...
3BPharmaceuticals GmbH es una empresa de biotecnología alemana que desarrolla radiofármacos terapéuticos y de diagnóstico innovadores para aplicaciones oncológicas. Utilizando su plataforma tecnológica dedicada, 3BP desarrolló una amplia gama de compuestos novedosos que abordan objeti...
3-M Company | 4adi | 4rtilab | 5 prime | 5prime | a & g pharmaceuticals | A&D Weighing | a.g scientific | Aalto | Aalto Scientific | aaltoscientific | aat bioquest | aat bioquest inc | AB Biolabs | ab peptides | ab sciex | abbexa | abbiotec | abbott laboratories | abcore-inc...
3B Pharmaceuticals GmbH is a privately held pharmaceutical R&D company based in Berlin, Germany.
3-M Company | 4adi | 4rtilab | 5 prime | 5prime | a & g pharmaceuticals | A&D Weighing | a.g scientific | Aalto | Aalto Scientific | aaltoscientific | aat bioquest | aat bioquest inc | AB Biolabs | ab peptides | ab sciex | abbexa | abbiotec | abbott laboratories | abcore-inc...
an employee of Genentech, Inc. W.S. is an employee of the California Institute for Biomedical Research. H.M.S. is an employee of the Novartis Institutes for BioMedical Research. B.H. serves as a consultant for Janssen Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Sanofi-Aventis ...
Variant Pharmaceuticals, Inc. has licensed worldwide rights to develop and commercialize hydroxypropyl-beta-cyclodextrin for treatment of kidney disease from L&F Research. S.M. holds equity interest in a company presently commercializing the form of cyclodextrin referenced in this paper. The patent ...
Current address: Department of Antisense Drug Discovery, Ionis Pharmaceuticals, Inc., Carlsbad, CA, USA. Current address: City of Hope – Beckman Research Institute, Duarte, CA, USA. Current address: J Craig Venter Institute, La Jolla, CA, USA. Authors and Affiliations Department of Reproductive...
这些研究计划也反映出罗氏未来在自免领域的开拓重点——免疫性肾病。反义疗法sefaxersen就切中了该布局方向,这款药物诞生在罗氏与Ionis Pharmaceuticals合作的基础上,主要用于IgA肾病。 ▍NO.4 诺华 诺华的自免业务正在冲刺百亿美元大关,2024年以21%的增长速度实现92.93...
Patent; BAYER PHARMACEUTICALS CORPORATION; Publ.: WO2005/35507A2 (2005/04/21), Appl.: WO2004-US33430 (2004/10/08). To a cloudy solution of 4- {4- [ (2-amino-6-phenylpyrimidin-4-yl) amino] phenoxy} pyridine-2-carboxylic acid (748 mg, 1.87 mmol, Example ...